8-KAcquisitions & DispositionsMaterial AgreementsOther Events+1

BIOGEN INC. 8-K Report, Material Agreement (Feb 2, 2017)

Filed February 2, 2017For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on February 2, 2017, to report the completion of a significant strategic transaction: the separation of its hemophilia business into a new, independent, publicly traded company, Bioverativ Inc. This separation was executed through a dividend-in-kind, where Biogen stockholders of record as of January 17, 2017, received one share of Bioverativ common stock for every two shares of Biogen stock they held. This move effectively spins off the hemophilia assets and liabilities, allowing Biogen to focus on its core biotechnology pipeline. The separation agreement, effective January 31, 2017, outlines the terms and conditions for this separation, including the transfer of specific assets and liabilities, and establishes non-solicitation and non-compete provisions between the two entities for a limited period. The completion of this separation on February 1, 2017, signifies a strategic shift for Biogen, potentially unlocking value by allowing each company to pursue its distinct growth strategies.

Key Highlights

  • 1Biogen completed the separation of its hemophilia business into a new independent company, Bioverativ Inc., on February 1, 2017.
  • 2Biogen stockholders received one share of Bioverativ common stock for every two shares of Biogen stock held as of January 17, 2017.
  • 3A separation agreement was entered into with Bioverativ, detailing asset and liability allocations and operational terms.
  • 4Biogen and Bioverativ are subject to nine-month non-solicit and two-year non-compete restrictions post-separation.
  • 5The transaction was structured as a dividend-in-kind distribution of Bioverativ's common stock to Biogen shareholders.
  • 6Biogen issued a press release on February 1, 2017, to announce the completion of this strategic separation.

Frequently Asked Questions

The primary purpose of this 8-K filing was to officially report the completion of Biogen's strategic separation of its hemophilia business into a new, independent company called Bioverativ Inc.

Biogen shareholders received shares of Bioverativ Inc. as a dividend-in-kind. Specifically, they received one share of Bioverativ common stock for every two shares of Biogen common stock they owned as of the record date (January 17, 2017).

Biogen and Bioverativ have entered into mutual restrictions that include a nine-month non-solicitation period and a two-year non-compete period following the separation.

The separation agreement, dated January 31, 2017, outlines the principal actions related to the separation, including the identification and transfer of specific assets and liabilities to each company, and the assignment of contracts.